Rezdiffra Approval Sheds Light on the Challenges of NASH Diagnosis and Fibrosis Identification The recent approval of Rezdiffra (resmetirom), a novel therapeutic for the treatment of non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis, marks a significant milestone in the fight against this increasingly prevalent liver disease. However, the journey to this point underscores the persistent challenges faced by healthcare professionals in diagnosing NASH and identifying fibrosis Read more
Сlinical Trials in Georgia 2024 Georgia, a country nestled between Eastern Europe and Western Asia, has emerged as a promising destination for clinical trials. With its strategic location and favorable regulatory environment, Georgia has become increasingly attractive to international sponsors seeking to conduct innovative research projects. Since 2013, Cromos Pharma has been at the forefront of managing clinical research in Read more
Clinical Research Focus. 27th Edition Navigating the Challenges: The Impact of US-China Tensions on Biopharmaceutical Innovation The escalating tensions between the US and China have permeated various sectors, including the biopharmaceutical industry, significantly impacting companies with footprints in both countries. This article explores the implications of these tensions, focusing on the case of WuXi AppTec and the Biotechnology Read more
Navigating the Challenges: The Impact of US-China Tensions on Biopharmaceutical Innovation The escalating tensions between the US and China have permeated various sectors, including the biopharmaceutical industry, significantly impacting companies with footprints in both countries. This piece explores the implications of these tensions, focusing on the case of WuXi AppTec and the Biotechnology Innovation Organization’s (BIO) recent decision to sever ties. The BIO-WuXi Clash: What’s Going Read more
